Found: 23
Select item for more details and to access through your institution.
Protein C system in preterm babies with chronic lung disease: Prospective study.
- Published in:
- Pediatrics International, 2022, v. 64, n. 1, p. 1, doi. 10.1111/ped.15221
- By:
- Publication type:
- Article
A microchip flow‐chamber assay screens congenital primary hemostasis disorders.
- Published in:
- Pediatrics International, 2021, v. 63, n. 2, p. 160, doi. 10.1111/ped.14378
- By:
- Publication type:
- Article
Prediction of the haemostatic effects of bypassing therapy using comprehensive coagulation assays in emicizumab prophylaxis‐treated haemophilia A patients with inhibitors.
- Published in:
- British Journal of Haematology, 2020, v. 190, n. 5, p. 727, doi. 10.1111/bjh.16574
- By:
- Publication type:
- Article
Comprehensive coagulation and fibrinolytic potential in the acute phase of pediatric patients with idiopathic nephrotic syndrome evaluated by whole blood-based rotational thromboelastometry.
- Published in:
- Pediatric Nephrology, 2022, v. 37, n. 7, p. 1605, doi. 10.1007/s00467-021-05366-4
- By:
- Publication type:
- Article
Screening of the protein C pathway abnormality‐related thrombophilia by using thrombomodulin‐mediated tissue factor‐triggered clot waveform analysis.
- Published in:
- European Journal of Haematology, 2022, v. 109, n. 1, p. 100, doi. 10.1111/ejh.13777
- By:
- Publication type:
- Article
Changes in coagulation potential over time after administration of recombinant activated factor VII in an emicizumab-treated hemophilia A patient with inhibitors.
- Published in:
- International Journal of Hematology, 2024, v. 120, n. 5, p. 639, doi. 10.1007/s12185-024-03828-7
- By:
- Publication type:
- Article
Emicizumab-mediated hemostatic function assessed by thrombin generation assay in an in vitro model of factor VIII-depleted thrombophilia plasma.
- Published in:
- International Journal of Hematology, 2024, v. 119, n. 2, p. 109, doi. 10.1007/s12185-023-03683-y
- By:
- Publication type:
- Article
Longitudinal dynamic changes in factor VIII inhibitor titers in patients with hemophilia A and inhibitors receiving emicizumab prophylaxis.
- Published in:
- International Journal of Hematology, 2023, v. 118, n. 6, p. 690, doi. 10.1007/s12185-023-03667-y
- By:
- Publication type:
- Article
High levels of factor VIII activity in patients with acquired hemophilia A in remission are associated with unusually low coagulation potentials.
- Published in:
- International Journal of Hematology, 2023, v. 117, n. 5, p. 669, doi. 10.1007/s12185-022-03528-0
- By:
- Publication type:
- Article
Two pediatric cases of severe hemophilia A in which emicizumab prophylaxis failed to prevent traumatic extra-articular hemorrhage.
- Published in:
- International Journal of Hematology, 2023, v. 117, n. 4, p. 607, doi. 10.1007/s12185-022-03490-x
- By:
- Publication type:
- Article
A case of a young boy with hyper-fibrinolysis associated with natural fibrin precipitates suspected to have occurred through a novel coagulation and fibrinolysis mechanism.
- Published in:
- 2022
- By:
- Publication type:
- journal article
The balance of comprehensive coagulation and fibrinolytic potential is disrupted in patients with moderate to severe COVID-19.
- Published in:
- International Journal of Hematology, 2022, v. 115, n. 6, p. 826, doi. 10.1007/s12185-022-03308-w
- By:
- Publication type:
- Article
Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients.
- Published in:
- International Journal of Hematology, 2022, v. 115, n. 4, p. 489, doi. 10.1007/s12185-021-03276-7
- By:
- Publication type:
- Article
Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Clot waveform analysis for perioperative hemostatic monitoring of arthroscopic synovectomy in a pediatric patient with hemophilia A and inhibitor receiving emicizumab prophylaxis.
- Published in:
- International Journal of Hematology, 2021, v. 113, n. 6, p. 930, doi. 10.1007/s12185-021-03095-w
- By:
- Publication type:
- Article
Evaluation of clinical severity in patients with type 2N von Willebrand disease using microchip-based flow-chamber system.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Coagulant potentials of emicizumab in the plasmas from infant and toddler patients with hemophilia A.
- Published in:
- Pediatric Blood & Cancer, 2023, v. 70, n. 10, p. 1, doi. 10.1002/pbc.30590
- By:
- Publication type:
- Article
Transversal family of non-autonomous conformal iterated function systems.
- Published in:
- Journal of Fractal Geometry, 2024, v. 11, n. 1/2, p. 57, doi. 10.4171/JFG/144
- By:
- Publication type:
- Article
Hybrid human‐porcine factor VIII proteins partially escape the inhibitory effects of anti‐factor VIII inhibitor alloantibodies having A2 or C2 domain specificity.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 140, doi. 10.1111/hae.14911
- By:
- Publication type:
- Article
Coagulation potentials of plasma‐derived factors VIIa and X mixture (Byclot<sup>®</sup>) evaluated by global coagulation assay in patients with acquired haemophilia A.
- Published in:
- Haemophilia, 2024, v. 30, n. 1, p. 249, doi. 10.1111/hae.14902
- By:
- Publication type:
- Article
Intra‐articular haemorrhage caused by reduced recovery of PEGylated recombinant factor VIII due to an anti‐PEG antibody developed after mRNA‐1273 SARS‐CoV‐2 vaccination in haemophilia A.
- Published in:
- Haemophilia, 2023, v. 29, n. 3, p. 935, doi. 10.1111/hae.14786
- By:
- Publication type:
- Article
In vitro evaluation of global coagulation potentials in the co‐presence of plasma‐derived factors Viia/X products (Byclot<sup>®</sup>) and emicizumab in patients with haemophilia A and inhibitors and acquired haemophilia A: A pilot study.
- Published in:
- Haemophilia, 2022, v. 28, n. 5, p. e149, doi. 10.1111/hae.14650
- By:
- Publication type:
- Article
Whole blood ristocetin‐induced platelet impedance aggregometry does not reflect clinical severity in patients with type 1 von Willebrand disease.
- Published in:
- Haemophilia, 2019, v. 25, n. 3, p. e174, doi. 10.1111/hae.13725
- By:
- Publication type:
- Article